12 results on '"Mugneret, F"'
Search Results
2. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique.
- Author
-
Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, Le Mée F, Plessis G, Talmant P, Gachard N, Uettwiller F, Pages MP, Mozziconacci MJ, Eclache V, Sibille C, Avet-Loiseau H, and Lafage-Pochitaloff M
- Subjects
- Acute Disease, Adolescent, Aged, Aged, 80 and over, Child, Female, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Leukemia immunology, Male, Middle Aged, CD4 Antigens analysis, CD56 Antigen analysis, Chromosome Aberrations, Leukemia genetics
- Abstract
CD4(+), CD56(+) DC2 malignancies constitute a novel disease entity, which has recently been shown to arise from a transformed lymphoid-related plasmacytoid dendritic cell (DC2). Diagnosis is primarily based on a particular immunophenotype with tumor cells expressing CD4 and CD56 antigens in the absence of common lymphoid or myeloid lineage markers. Little is currently known about the cytogenetic features of this disease entity. In this setting, the Groupe Français de Cytogénétique Hématologique (GFCH) initiated a cytogenetic study of 18 adults and 3 children with CD4(+), CD56(+) DC2 acute leukemia using conventional and fluorescence in situ hybridization/24-color karyotyping. Clonal, mostly complex chromosome aberrations were found in 14 patients (66%). Six major recurrent chromosomal targets were defined. These were 5q, 12p, 13q, 6q, 15q, and 9, which were involved in 72% (5q), 64% (12p and 13q), 50% (6q), 43% (15q), and 28% (monosomy 9) of cases, respectively. Cytogenetic features can be summarized as follows: (1) gross genomic imbalances (mostly losses) predominate, (2) no single anomaly can be considered as specific, whereas their combination/accumulation is, and (3) both lymphoid and myeloid lineage-associated rearrangements are observed in unusual combinations in the same cell. This is suggestive of complex multistep tumorigenic mechanisms and is supportive of the hypothesis that CD4(+), CD56(+) DC2 acute leukemia may arise from an undifferentiated nonmyeloid nonlymphoid progenitor cell. In conclusion, the present study documents for the first time the existence of a characteristic cytogenetic profile for this novel disease entity.
- Published
- 2002
- Full Text
- View/download PDF
3. MLL amplification in acute leukaemia: a United Kingdom Cancer Cytogenetics Group (UKCCG) study.
- Author
-
Cuthbert G, Thompson K, McCullough S, Watmore A, Dickinson H, Telford N, Mugneret F, Harrison C, Griffiths M, and Bown N
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Blotting, Southern, Child, Child, Preschool, Chromosomes, Human, Pair 11 ultrastructure, Extrachromosomal Inheritance, Female, Histone-Lysine N-Methyltransferase, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Leukemia mortality, Male, Middle Aged, Myeloid-Lymphoid Leukemia Protein, Survival Analysis, United Kingdom epidemiology, Chromosomes, Human, Pair 11 genetics, DNA-Binding Proteins genetics, Gene Amplification, Leukemia genetics, Proto-Oncogenes, Transcription Factors
- Abstract
The MLL gene, located at 11q23, is frequently rearranged in acute leukaemia as either chimaeric fusion genes or partial tandem duplications. We report a series of 12 acute leukaemia cases with apparent amplification of the MLL gene ascertained using fluorescence in situ hybridisation (FISH). Seven cases showed intrachromosomal amplification of MLL, four cases showed extrachromosomal amplification as double minute chromosomes (dmin) and one case had separate subclones with dmin and homogenously staining region (hsr). Southern blot analysis of the MLL gene showed MLL gene rearrangement in three of the 10 successful cases. These cases do not naturally fall into either of the two recognised categories of MLL rearrangement and may represent a third variety of MLL gene abnormalities.
- Published
- 2000
- Full Text
- View/download PDF
4. Increase therapy-related leukemia secondary to breast cancer.
- Author
-
Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, and Maynadié M
- Subjects
- Breast Neoplasms drug therapy, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Combined Modality Therapy, Female, Humans, Antineoplastic Agents adverse effects, Breast Neoplasms therapy, Leukemia chemically induced, Neoplasms, Second Primary chemically induced
- Abstract
Therapy-related leukemia associated with chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, are being reported with increasing frequency in the literature mainly after breast cancer. We also observed an increasing number of such leukemias in the data base of the specialized registry of hematological malignancies of the Côte d'Or department. Between 1980 and 1998, 156 AML and RAEB-t were registered in women in Côte d'Or. Among them, 12 occurred in women with breast cancer history (7.7%). Analysis by period of time shows a significant increase in the proportion of therapy-related leukemia secondary to breast cancer (P < 0.02). Chemotherapy including topoisomerase II inhibitors was used in 10 cases in which mitoxantrone was used in eight cases. In these eight cases, leukemia had clinical and biological characteristics usually described with topoisomerase II inhibitors but 44% were promyelocytic sub-type with the t(15;17) specific karyotypic abnormality. These data on a well-defined population demonstrate the increased proportion of therapy-related leukemia secondary to breast cancer, probably due to the use of mitoxantrone.
- Published
- 2000
- Full Text
- View/download PDF
5. [Constitutional chromosome anomalies and acute leukemia].
- Author
-
Turc-Carel C, Mugneret F, and Sidaner I
- Subjects
- Acute Disease, Chromosome Disorders, Humans, Sex Chromosome Aberrations complications, Translocation, Genetic, Chromosome Aberrations complications, Down Syndrome complications, Leukemia genetics
- Abstract
A review on the association between acute leukemias (AL) and constitutional chromosome abnormalities (CCA) is presented. AL, myeloblastic or lymphoblastic according to age are 18 to 20 times more frequent in Down Syndrome (DS) children than in non DS children. The incidence of acquired chromosome abnormalities is similar in leukemic cells of DS and non DS patients but the type of anomalies, in the leukemic myeloblastic cells of DS, are different : hyperdiploidy, excess of C, F and G. Gain of chromosomes 8, 19 and 22 would characterize leukemic myeloblasts in an early stage of differentiation. Recent data on transient leukemoid reactions show that a 21 in DS appears to be predisposing factor in the development of AL. Association between AL and other balanced or unbalanced CCA appears until now to be fortuitous.
- Published
- 1983
6. [Constitutional chromosome abnormalities and acute leukemia].
- Author
-
Turc-Carel C, Mugneret F, and Sidaner I
- Subjects
- Acute Disease, Adolescent, Adult, Child, Child, Preschool, Chromosome Banding, Chromosome Disorders, Down Syndrome genetics, Humans, Infant, Infant, Newborn, Leukemoid Reaction genetics, Chromosome Aberrations genetics, Leukemia genetics
- Abstract
A review on the association between acute leukemias (AL) and constitutional chromosome abnormalities (CCA) is presented. AL, myeloblastic or lymphoblastic according to age are 16 to 20 times more frequent in Down Syndrome (DS) children than in non DS children. The incidence of acquired chromosome abnormalities is similar in leukemic cells of DS and non DS patients but the type of anomalies, in the leukemic myeloblastic cells of DS, are different: hyperdiploidy, excess of C, F and G. Gain of chromosomes 8, 19 and 22 would characterize leukemic myeloblasts in an early stage of differentiation. Recent data on transient leukemoid reactions show that a 21 in DS appears to be predisposing factor in the development of AL. Association between AL and other balanced or unbalanced CCA appears until now to be fortuitous.
- Published
- 1982
7. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique
- Author
-
Romana, S P, Radford-Weiss, I, Ben Abdelali, R, Schluth, C, Petit, A, Dastugue, N, Talmant, P, Bilhou-Nabera, C, Mugneret, F, Lafage-Pochitaloff, M, Mozziconacci, M-J, Andrieu, J, Lai, J-L, Terre, C, Rack, K, Cornillet-Lefebvre, P, Luquet, I, Nadal, N, Nguyen-Khac, F, Perot, C, Van den Akker, J, Fert-Ferrer, S, Cabrol, C, Charrin, C, Tigaud, I, Poirel, H, Vekemans, M, Bernard, O A, and Berger, R
- Published
- 2006
- Full Text
- View/download PDF
8. Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRβ-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique.
- Author
-
Cauwelier, B., Cavé, H., Gervais, C., Lessard, M., Barin, C., Perot, C., Van den Akker, J., Mugneret, F., Charrin, C., Pagès, M. P., Grégoire, M.-J., Jonveaux, P., Lafage-Pochitaloff, M., Mozzicconacci, M. J., Terré, C., Luquet, I., Cornillet-Lefebvre, P., Laurence, B., Plessis, G., and Lefebvre, C.
- Subjects
CYTOGENETICS ,CELL receptors ,LEUKEMIA ,CARCINOGENESIS ,MOLECULAR genetics ,IN situ hybridization ,BONE marrow ,IMMUNOPHENOTYPING - Abstract
Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRβ) (7q34) and the HOXA gene locus (7p15) in 5% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRβ-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2% of cases including all the cases with a TCRβ-HOXA rearrangement (8.2%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRβ-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRβ-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRβ-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67%, respectively. In conclusion, this study defines TCRβ-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.Leukemia (2007) 21, 121–128. doi:10.1038/sj.leu.2404410; published online 12 October 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
9. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
- Author
-
Terre, C., Eclache, V., Rousselot, P., Imbert, M., Charrin, C., Gervais, C., Mozziconacci, M. J., Maarek, O., Mossafa, H., Auger, N., Dastugue, N., Talmant, P., Van Den Akker, J., Leonard, C., N'Guyen Khac, F., Mugneret, F., Viguié, F., Lafage-Pochitaloff, M., Bastie, J. N., and Roux, G. l.
- Subjects
IMATINIB ,MYELOID leukemia ,PROTEIN-tyrosine kinases ,CHROMOSOMES ,ANTINEOPLASTIC agents ,LEUKEMIA - Abstract
Imatinib mesylate (Gleevec
® ), an inhibitor of the BCR-ABL tyrosine kinase, was introduced recently into the therapy of chronic myeloid leukemia (CML). Several cases of emergence of clonal chromosomal abnormalities after therapy with imatinib have been reported, but their incidence, etiology and prognosis remain to be clarified. We report here a large series of 34 CML patients treated with imatinib who developed Philadelphia (Ph)-negative clones. Among 1001 patients with Ph-positive CML treated with imatinib, 34 (3.4%) developed clonal chromosomal abnormalities in Ph-negative cells. Three patients were treated with imatinib up-front. The most common cytogenetic abnormalities were trisomy 8 and monosomy 7 in twelve and seven patients, respectively. In 15 patients, fluorescent in situ hybridization with specific probes was performed in materials archived before the initiation of imatinib. The Ph-negative clone was related to previous therapy in three patients, and represented a minor pre-existing clone that expanded after the eradication of Ph-positive cells with imatinib in two others. However, in 11 patients, the new clonal chromosomal abnormalities were not detected and imatinib may have had a direct effect. No myelodysplasia was found in our cohort. With a median follow-up of 24 months, one patient showed CML acceleration and two relapsed.Leukemia (2004) 18, 1340-1346. doi:10.1038/sj.leu.2403399 Published online 10 June 2004 [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
10. Ten novel 11q23 chromosomal partner sites. European 11q23 Workshop participants.
- Author
-
Harrison, C J, Cuneo, A, Clark, R, Johansson, B, Lafage-Pochitaloff, M, Mugneret, F, Moorman, A V, and Secker-Walker, L M
- Subjects
GENES ,LEUKEMIA ,CHROMOSOMES ,MYELODYSPLASTIC syndromes ,PROTEINS ,DNA ,LYMPHOBLASTIC leukemia ,ONCOGENES ,MYELOID leukemia ,CHROMOSOME banding ,KARYOTYPES ,CHROMOSOME abnormalities ,TRANSFERASES ,DNA-binding proteins ,TRANSCRIPTION factors ,ACUTE diseases - Abstract
The MLL gene located at 11q23 has been described as a 'promiscuous' gene due its involvement with a large number of genetic partners. The EU Concerted Action Workshop on 11q23 provided 550 cases for study of which 82 showed abnormalities which did not involve the established translocations or deletion of 11q23. In these 'other' cases, which included inversions and duplications, 11q23 was found to be involved with 25 chromosome partners of which 10 had not been previously reported. These were 1q31, 4p11, 6q13, 8q21, 10q22, 10q25, 11q11, 11q21, 13q34 and 18q23. This study demonstrated the value of the Workshop, in confirming the diversity of chromosomal partner sites involved with 11q23 and in the identification of new partners. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
11. Minimally differentiated acute myeloid leukemia (AML-MO) with lymphoid presentation at relapse: a case report.
- Author
-
Ysebaert, L, Carli, P M, Casasnovas, R O, Girodon, F, Caillot, D, Mugneret, F, and Maynadié, M
- Subjects
LEUKEMIA ,DISEASE relapse ,LYMPHOBLASTIC leukemia diagnosis ,BONE marrow ,CELL differentiation ,CELLS ,FLOW cytometry ,GENETICS ,IMMUNOPHENOTYPING ,LYMPHOBLASTIC leukemia ,MYELOID leukemia ,ACUTE diseases ,SECONDARY primary cancer - Abstract
Presents the case study of a person diagnosed with minimally differentiated acute myeloid leukemia at relapse. Treatment given to the patient during the initial diagnosis of leukemia; Relapse of acute leukemia in the patient after ten months of completion of treatment; Diagnosis of B III acute lymphoid leukemia on relapse.
- Published
- 2001
- Full Text
- View/download PDF
12. Cytogenetic study of 75 erythroleukemias
- Author
-
Lessard, M., Struski, S., Leymarie, V., Flandrin, G., Lafage-Pochitaloff, M., Mozziconacci, M.-J., Talmant, P., Bastard, C., Charrin, C., Baranger, L., Hélias, C., Cornillet-Lefebvre, P., Mugneret, F., Cabrol, C., Pagès, M.-P., Fert-Ferret, D., Nguyen-Khac, F., Quilichini, B., Barin, C., and Berger, R.
- Subjects
- *
GENETICS , *CELL nuclei , *LEUKEMIA , *CHROMOSOME abnormalities - Abstract
Abstract: Chromosomal abnormalities of erythroleukemia (EL) are often described as complex and unspecific. A retrospective study of 75 EL defined following the WHO classification was performed by the Groupe Francophone de Cytogénétique Hématologique (GFCH) in order to reexamine the cytogenetics of this infrequent leukemia subtype. Clonal chromosomal abnormalities were found in 57 patients (76%), distributed in 4 subgroups according to their ploidy status: pseudodiploid (16%), hypodiploid (47%), hyperdiploid (19%), and 18% mixed cases associating 2 different clones (hypodiploid + hyperdiploid) or (pseudodiploid + hyperdiploid). Complex rearrangements and hypodiploid chromosome number were widely dominant (50%). Partial or entire monosomies represented 56% of abnormalities. Chromosomes 5 and 7 were the most frequently involved (41 and 33 times, respectively), followed by chromosomes 8, 16, and 21 (19 times each). Unbalanced abnormalities were more frequent than balanced. All these kinds of abnormalities were observed in de novo as well as in secondary EL. Four out of 7 cases of “pure erythroid” leukemia were associated with a BCR-ABL fusion. Lastly, no chromosome abnormality specific to EL could be established. However, the large overlap of chromosomal abnormality patterns of EL (pure erythroid form excepted) and refractory anemia with excess of blasts in transformation (RAEB-t) favors the hypothesis of similarities between these 2 hematologic disorders. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.